Shanghai Junshi Biosciences Co Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Junshi Biosciences Announces NDA Acceptance in Hong Kong

SHANGHAI, China, April 24, 2024 (GLOBE NEWSWIRE) Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading.

United statesUnited kingdomSan franciscoHong kong special administrative regionHong kong generalHong kongSouth africaZhi liJunshi biosciencesAmerican society of clinical oncologyNational reimbursement drug listDrug officeDepartment of healthIr teamEuropean unionAustralia therapeutic goods administration

Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab

Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Hong kong special administrative regionHong kong generalHong kongSouth africaSan franciscoUnited statesUnited kingdomJunshi biosciencesZhi liDennis riedlIr teamAustralia therapeutic goods administrationEuropean unionAmerican society of clinical oncologyJournal of the american medical associationWorld health organization

Toripalimab Plus Axitinib Approved in China for Frontline Renal Cell Carcinoma

The NMPA of China has approved toripalimab plus axitinib for use in the first-line treatment of patients with medium- to high-risk unresectable or metastatic RCC.

Jun guoNational medical products administration of chinaShanghai junshi biosciences co ltdUniversity cancer hospitalInternational metastatic renal cell carcinoma database consortiumNational medical products administrationPeking university cancer hospitalGlobal oncologyImmuno oncologyGenitourinary cancersToripalimab plus axitinibFirst line treatment of patients with medium to high risk unresectable or metastatic rccThe national medical products administration of china

Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer By Investing com

Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer By Investing com
investing.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investing.com Daily Mail and Mail on Sunday newspapers.

United statesSan franciscoPabout toripalimabJunshi bioscienceszhiJunshi biosciencesSingapore health sciences authorityUniversity cancer hospitalJunshi biosciences contact informationir teamEuropean medicines agencyAustralia therapeutic goods administrationInternational metastatic renal cell carcinoma database consortiumPr teamNational medical products administrationShanghai junshi biosciences co ltdNational reimbursement drug listProfessor jun

Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer

Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesSan franciscoJunshi biosciencesZhi liAustralia therapeutic goods administrationShanghai junshi biosciences co ltdUniversity cancer hospitalIr teamPr teamSingapore health sciences authorityInternational metastatic renal cell carcinoma database consortiumNational reimbursement drug listNational medical products administrationEuropean medicines agencyBiosciences announces approvalLine treatment